**Appendix 7** Outcomes of the one-way sensitivity analysis for the costs of ibuprofen versus indomethacin and ibuprofen versus paracetamol

**TABLE 1.** Variation range for variables used in one-way sensitivity analysis with outcomes of interest. (Ibuprofen versus indomethacin model)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variable | Value uncertainty range, QAR  (-90%- +10%) (USD [range]) | Average cost of oral ibuprofen, QAR (95%CI) (USD [95%CI]) | Average cost of IV indomethacin, QAR (95%CI) (USD [95%CI]) | Average cost of IV ibuprofen, QAR (95%CI) (USD [95%CI]) | ICER of oral ibuprofen and IV indomethacin, QAR (95%CI) (USD [95%CI]) | ICER of IV ibuprofen and IV indomethacin, QAR (95%CI) (USD [95%CI]) |
| Base-case |  | 414,761  (413,528- 415,994)  (113,945 [113,607-114,284]) | 436,158  (434,762- 437,554) (119,823 [119,440-120,207]) | 435,794  (434,427-437,163) (119,724 [119,348-120,099]) | Dominance for oral ibuprofen | 12,546 (-54,693- 79,785)  (3,447 [15,026-21,919]) with IV indomethacin |
| Oral ibuprofen acquisition cost | 2  (0.2-1.7)  (0.5 [0.04-0.5]) | 500,453  (499,195-501,710.7)  (137,487 [137,141-137,833]) | 516,743  (515,336- 518,150)  (141,962 [141,575-142,348]) | 517,418  (516,007- 518,829)  (142,148 [141,760-142,535]) | Dominance for oral ibuprofen | Dominance for IV indomethacin |
| IV indomethacin acquisition cost | 2,220  (222-2,442)  (610 [61-665]) | 500, 804  (499,549-502,059)  (137,584 [137,239-137,928]) | 514,986  (513,597- 516,375)  (141,480 [141,098-141,861]) | 517,456  (516,047-518,866)  (142,158 [14,176-142,545]) | Dominance for oral ibuprofen | Dominance for IV indomethacin |
| IV ibuprofen acquisition cost | 553  (55-608)  (152 [15-167]) | 499,934  (498,680- 501,188)  (137,344 [137,000-137,689]) | 516,802  (515,410-518,194)  (141,979 [141,596-142,360]) | 517,488  (516,113-518,863)  (142,167 [141,789-142,545]) | Dominance for oral ibuprofen | Dominance for IV indomethacin |
| Oral paracetamol acquisition cost | 3  (0.3-3.1)  (0.8 [0.1-0.9]) | 500,535  (499,312- 501,758)  (137,510 [137,174-137,846]) | 517,132  (515,724- 518,540)  (142,069 [141,682-142,456]) | 516,587  (515,206-515,206)  (141,920 [141,540-141,540]) | Dominance for oral ibuprofen | 18,795 (-49,754-87,344)  (5,163 [-13,668-23,995])  with IV indomethacin |
| ICER: incremental cost-effectiveness ratio, QAR: Qatari riyal, USD: United state dollars, 95%CI: 95 % confidence interval, IV: intravenous | | | | | | |

**TABLE 2.** Variation range for variables used in one-way sensitivity analysis with outcomes of interest. (Ibuprofen versus paracetamol model)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Value, uncertainty range, QAR  (-90%- +10%) (USD [range]) | Average cost of oral ibuprofen, QAR (95%CI) (USD [95%CI]) | Average cost of oral paracetamol, QAR (95%CI) (USD [95%CI]) | Average cost of IV ibuprofen, QAR (95%CI) (USD [95%CI]) | ICER of oral ibuprofen and oral paracetamol, QAR (95%CI) (USD [95%CI]) | ICER of IV ibuprofen and oral paracetamol, QAR (95%CI) (USD [95%CI]) |
| Base-case |  | 404,970  (393,834- 416,106)  (111,255 [108,196-114,315]) | 397,798  (386,363- 409,233)  (109,285 [106,143-112,426]) | 415,588  (403,174- 428,002)  (114,173 [110,762-117,582]) | Dominance for oral paracetamol | Dominance for oral paracetamol |
| Oral ibuprofen acquisition cost | 2  (0.2-1.7)  (0.5 [0.04-0.5]) | 507,472  (506,277-508,667)  (139,415 [139,087-139,743]) | 489,161  (487,921- 490,400)  (134,385 [134,044-134,725]) | 490,659  (489,321- 491,997)  (134,796 [134,429-135,164]) | Dominance for oral paracetamol | Dominance for oral paracetamol |
| IV indomethacin acquisition cost | 2,220  (442-222,2)  (610 [121-610]) | 507,495  (506,322- 508,668)  (139,422 [139,099-139,744]) | 419,396  (490,167- 492,625)  (115,219 [134,661-135,336]) | 488,975  (487,639- 490,311)  (134,334 [133,966-134,700]) | Dominance for oral paracetamol | Dominance for oral paracetamol |
| IV ibuprofen acquisition cost | 553  (55-608)  (152 [15-167]) | 508,042  (506,858- 509,225)  (139,572 [139,246-139,897]) | 488,762  (487,531- 489,993)  (134,275 [133,937-134,613]) | 489,032  (487,692-490,372)  (134,349 [133,981-134,717]) | Dominance for oral paracetamol | Dominance for oral paracetamol |
| Oral paracetamol  acquisition cost | 3  (0.3-3.1)  (0.8 [0.1-0.9]) | 507,481  (506,287- 508,675)  (139,418 [139,089-139,745]) | 489,474  (515,724- 518,540)  (134,471 [141,682-142,456]) | 491,064  (489,719- 492,409)  (134,908 [134,538-135,277]) | Dominance for oral paracetamol | Dominance for oral paracetamol |
| ICER: incremental cost-effectiveness ratio, QAR: Qatari riyal, USD: United state dollars, 95%CI: 95 % confidence interval, IV: intravenous | | | | | | |